Skip to main content

Refractory Infantile Spasms clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

    open to eligible people ages 6 months to 36 months

    This open label, multicenter study allows JBPOS0101 (investigational product) to be given as either add-on therapy or monotherapy for patients with refractory infantile spasms. The design and choice of study population of this Phase 2 clinical study is based on the need to provide initial safety, tolerability, pharmacokinetics (PK), and efficacy outcomes of the investigational product for future clinical studies.

    San Francisco, California and other locations

Last updated: